News Stories

Sep, 2023

The United States Preventive Services Task Force (USPSTF) recently released its Final Recommendation Statement on Lipid Disorders in Children and Adolescents: Screening. NLA leadership disagrees with this release and communicated twice to USPSTF about the implications of this statement. The USPSTF has made no acknowledgment of the NLA’s concerns.

0
No votes yet
Name: NLA News
Jul, 2023

Novartis received FDA approval for a label update that will allow for use of Leqvio ® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.

0
No votes yet
Name: NLA News
Feb, 2023

 

 

LEVERAGING IMPLEMENTATION SCIENCE 

0
No votes yet
Name: NLA News